Auxilium Pharmaceuticals (AUXL) Provides FY11 Revenue Update

Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) forecasts preliminary unaudited global net revenues for full year 2011 should be above the midpoint of previously announced guidance of $254 million to $271 million and are likely to be slightly above the 2011 analyst consensus of $263.9 million; (ii) preliminary unaudited global net revenues for Testim for the full year 2011 should be above the midpoint of the previously announced guidance of $200 million to $210 million and are likely to be slightly above 2011 analyst consensus of $206.5 million; and (iii) preliminary unaudited U.S. net revenues for XIAFLEX should be below previously announced guidance of $45 million to $50 million and are likely to be slightly below the 2011 analyst consensus of $44.2 million.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Monro Muffler (MNRO) Tops Q4 EPS by 1c; Comps About Flat; Guides FY13 EPS Below Views
• Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (AUXL); Bumping Guidance on Testim Partnership with GSK
• Flowers Foods, Inc. (FLO) Reports In-Line Q1 EPS; Adjusts FY12 EPS Growth Outlook

Create E-mail Alert Related Categories

Guidance

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter